Introduction
Experimental
Results
| Group | Treatment | Dose | Blood glucose level (mg/dl) | Average body weight (g) | ||||
|---|---|---|---|---|---|---|---|---|
| Week 0 | Week 3 | Week 6 | Week 0 | Week 3 | Week 6 | |||
| 1 | N+C | 10 ml/kg | 92.8±6.1 | 86.8±3.6 | 91.6±4.5 | 243.6±15.1 | 261±8.4 | 290.8±5.9& |
| 2 | N+B | 500 | 90.4±5.2 | 81.9±4. | 80.4±3.8 | 231.6±6.6 | 254±6.4 | 278.4±6.4& |
| 3 | D+C | 10 ml/kg | 80.8±5.4 | 291.8±8.9# | 305.5±10.1#& | 230.2±6.2 | 180±8.8#& | 150.4±6.75#& |
| 4 | D+Bb | 500 | 98.5±4.4 | 81.2±8.9* | 96.4±4.2* | 239.6±6.2 | 255±7.6* | 258.2±6.3* |
| 5 | D+Ba | 500 | 82.6±5.2 | 90.6±10.1* | 123.8±7.1* a& | 239.6±5.9 | 258±12.4* | 241.4±10.3* |
p<0.001: Diabetic control rats were compared with Normal control Rats on corresponding day,
p<0.001 Diabetic treated Rats were compared with Diabetic control Rats,
p<0.01: Diabetic rats + Barberry_ After were compared with Diabetic rats treated + barberry_ before and
p<0.001 compared to 0 value.
| Group | Treatment | Dose | liver parameters (mg/dl) | ||||
|---|---|---|---|---|---|---|---|
| ALP | ALT | AST | Total bilirubin | Total protein | |||
| 1 | N+C | 10 ml/kg | 99.08±6.17 | 52.62±3.08 | 39.86±4.97 | 1.59±0.13 | 7.51±0.41 |
| 2 | N+B | 500 | 91.42±2.17 | 50.18±5.01 | 35.18±5.09 | 1.30±0.11 | 7.53±0.44 |
| 3 | D+C | 10 ml/kg | 178.81±6.40# | 99.88±4.84# | 94.18±4.42# | 3.71±0.16# | 3.97±0.28# |
| 4 | D+Bb | 500 | 95.10±5.20c | 46.05±3.55c | 35.58±4.40c | 1.81±0.11c | 5.70±0.29a |
| 5 | D+Ba | 500 | 127.76±9.58c* | 66.91±3.91c* | 65.40±6.50b** | 2.74±0.19b** | 3.86±0.26* |
p<0.001 Diabetic control Rats were compared with Normal control Rats.
p<0.05 and
p<0.01,
p<0.001 Diabetic treated Rats were compared with Diabetic control Rats;
p<0.05 and
p<0.01 : Diabetic rats + Barberry_ After were compared with Diabetic rats treated + barberry_ before.
| Group | Treatment | Dose | MDA | SOD | CAT | GSH |
|---|---|---|---|---|---|---|
| 1 | N+C | 10 mL/Kg | 2.15±0.22 | 10.04±0.68 | 82.39±5.05 | 5.46±0.33 |
| 2 | N+B | 500 | 2.22±0.10 | 10.87±1.14 | 92.44±4.85 | 5.93±0.40 |
| 3 | D+C | 10 mL/Kg | 7.43±0.59# | 3.06±0.40# | 32.64±3.31# | 2.14±0.16# |
| 4 | D+Bb | 500 | 2.23±0.32c | 9.74±0.46c | 86.59±5.57c | 7.28±0.43c |
| 5 | D+Ba | 50 | 4.48±0.45c** | 6.32±0.61a* | 57.63±8.45 a* | 4.69±0.63b** |
p<0.001 Diabetic control Rats were compared with Normal control Rats.
p<0.05 and
p<0.01,
p<0.001 Diabetic treated Rats were compared with Diabetic control Rats;
p<0.05 and
p<0.01 : Diabetic rats + Barberry_ After were compared with Diabetic rats treated + barberry_ before.
Histopathologicalevalution of liver sections. Formalin fixed liver sections of 5 μ thickness fromcontrol and diabetic were stained with H&E and images were taken at the magnification of 400X. Various panelsrepresent control (A), treated control (B), diabetic control (C1, C2), diabetic treated rats [D+Bb group](D) and diabetic treated rats [D+Ba group] (E).Total loss of hepatic architecture (I) and lymphocytic inflammation (II).
 and diabetic treated rats [D+Ba group] (E).Total loss of hepatic architecture (I) and lymphocytic inflammation (II).](https://brieflands.com/journals/ijpr/articles/125278/figures/ijpr-14-335-g001-preview.webp)